Postoperative CMF Does Not Ameliorate Poor Outcomes in Women With Residual Invasive Breast Cancer After Neoadjuvant Epirubicin/Docetaxel Chemotherapy
Regina Promberger(Medical University of Vienna), Rupert Bartsch(Universitätszahnklinik Wien), Christian F. Singer(Comprehensive Cancer Center Vienna), Zsuzsanna Bagó-Horváth(Comprehensive Cancer Center Vienna), Michael Gnant(Austrian Breast & Colorectal Cancer Study Group), Rudolf Seemann(Medical University of Vienna), Elisabeth Bergen(Medical University of Vienna), Johannes Ott(Medical University of Vienna), Margaretha Rudas(Comprehensive Cancer Center Vienna), Ruth Exner(Comprehensive Cancer Center Vienna), Peter Dubsky(Hirslanden Klinik St. Anna), Martina Mittlböck(Medical University of Vienna), Günther Steger(Barwon Health), R. Jakesz(Comprehensive Cancer Center Vienna), Peter Panhofer(Medical University of Vienna)
Cited by 5
Related Papers
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Breast cancer
|The Lancet|2016|2.3k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k